Nov 30, 2012

Synthetic Vaccines Mutating Science

Get Vaccine Exemption Forms
Via:Sacbee
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon® DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases. Results from this preclinical study appear in the peer-reviewed journal, Human Vaccines & Immunotherapeutics, in an article entitled, "Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice."
 The genetic complexity of CMV has inhibited the advancement of vaccines for this disease. In this study, DNA vaccine constructs targeting multiple novel CMV antigens were created using Inovio's SynCon® vaccine platform. These SynCon constructs were administered via Inovio's proprietary electroporation-based delivery technology. The vaccine constructs were observed to induce strong and broad CD8+ and CD4+ T cells in an animal model. These findings are vital given the important role T cells play in clearing infection by killing cells that harbor the virus. This is especially crucial in protecting against diseases in different populations such as organ transplant patients that are at high risk from CMV infection.
Vaccine Exemption Forms

No comments:

Post a Comment